
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

May 2019

Commission File Number: 001-38067

**Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)**

**3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 7, 2019, Verona Pharma plc issued a press release announcing that all resolutions proposed at the Annual General Meeting were duly passed ("The AGM Results Announcement").

The AGM Results Announcement is furnished herewith as Exhibit 1 to this Report on Form 6-K.

This Report on Form 6-K, excluding Exhibit 1, is hereby incorporated by reference into the Company's Registration Statement on Form F-3 (File No. 333-225107).

EXHIBIT INDEX

Exhibit No.	Description
<u>1</u>	The AGM Results Announcement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERONA PHARMA PLC

Date: May 14, 2019

By: /s/ Claire Poll

Name: Claire Poll

Title: Legal Counsel



Verona Pharma

Result of AGM

May 7, 2019, LONDON - Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma may also develop ensifentrine for the treatment of cystic fibrosis and asthma.

For further information, please contact:

Verona Pharma plc

Jan-Anders Karlsson, Chief Executive Officer

Victoria Stewart, Director of Communications

Tel: +44 (0)20 3283 4200

info@veronapharma.com

N+1 Singer

(Nominated Adviser and UK Broker)

Aubrey Powell /Jen Boorer /Iqra Amin (Corporate

Finance) Brough Ransom /Mia Gardner (Corporate Broking)

Tel: +44 (0)20 3283 4200

Optimum Strategic Communications

(European Media and Investor enquiries)

Mary Clark, Anne Marieke Ezendam, Hollie Vile

Tel: +44 (0) 203 922 0891

verona@optimumcomms.com